Reformulated Vaccine Industry Grapples With Scientific, Regulatory, Reimbursement Challenges, But The Promise Is Great
This article was originally published in The Pink Sheet Daily
Opportunities are boundless in a resurging vaccines industry, but companies that enter face daunting science and a high regulatory bar as well as unmet needs - old challenges that will only increase for new next-generation products.
You may also be interested in...
The wave of new adjuvant-boosted vaccines under development promises to protect new and broader populations against a host of previously elusive pathogens - including pandemic flu. However, until FDA has more experience with these novel combinations, the regulatory hurdles will remain high, speakers warned at the recent Immunotherapeutics & Vaccine Summit in Cambridge, Mass
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.